Home

AXGN

(AXGN)

NCM – Real vaqt narxi. Valyuta: USD

31.28

-0.97 (-3.01%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

31.28

0.00 (0.00%)

Bozordan keyin: Mar 27, 2026, 4:34 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

AXGN - Axogen, Inc. So'nggi Yangiliklar | Finranks

Home

AXGN

(AXGN)

NCM – Real vaqt narxi. Valyuta: USD

31.28

-0.97 (-3.01%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

31.28

0.00 (0.00%)

Bozordan keyin: Mar 27, 2026, 4:34 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Videolar

No Data

There is no data to display

Press-relizlar

22.01.2026

Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock

ALACHUA, Fla. and TAMPA, Fla.

Videolar

No Data

There is no data to display

Press-relizlar

22.01.2026

Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock

ALACHUA, Fla. and TAMPA, Fla.

21.01.2026

Axogen Announces Proposed Public Offering of Common Stock

ALACHUA, Fla. and TAMPA, Fla.

12.01.2026

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

ALACHUA, Fla. and TAMPA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced preliminary unaudited fourth quarter and full-year 2025 key financials.

04.12.2025

Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)

ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of peripheral nerve function, today announced that the U.S. Food and Drug Administration (the “FDA”) has approved the Biologics License Application (“BLA”) for AVANCE® (acellular nerve allograft-arwx).